Login to Your Account

SHAPE-shifter Tetralogic: MDS phase II shuts down, promise for CTCL HDAC?

By Randy Osborne
Staff Writer

Thursday, January 7, 2016

Hopes that phase II data could "re-ignite the investment case" for Tetralogic Pharmaceuticals Corp. flamed out and the shares (NASDAQ:TLOG) plunged 76.1 percent, or $1.29, ending at 41 cents, as the firm offered mixed results from a pair of trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription